S&P 500   3,780.87 (-0.27%)
DOW   30,277.44 (-0.13%)
QQQ   280.67 (-0.52%)
AAPL   145.63 (-0.32%)
MSFT   248.12 (-0.31%)
META   138.05 (-1.59%)
GOOGL   100.75 (-0.88%)
AMZN   120.30 (-0.65%)
TSLA   238.25 (-4.49%)
NVDA   130.79 (-0.67%)
NIO   15.88 (-5.08%)
BABA   84.02 (-0.11%)
AMD   67.47 (-0.63%)
T   15.92 (-1.06%)
MU   54.44 (+0.89%)
CGC   3.02 (-3.82%)
F   12.43 (+0.57%)
GE   67.65 (+0.16%)
DIS   99.82 (-1.60%)
AMC   7.25 (-7.41%)
PYPL   93.49 (+0.75%)
PFE   44.05 (-0.92%)
NFLX   233.92 (-2.83%)
S&P 500   3,780.87 (-0.27%)
DOW   30,277.44 (-0.13%)
QQQ   280.67 (-0.52%)
AAPL   145.63 (-0.32%)
MSFT   248.12 (-0.31%)
META   138.05 (-1.59%)
GOOGL   100.75 (-0.88%)
AMZN   120.30 (-0.65%)
TSLA   238.25 (-4.49%)
NVDA   130.79 (-0.67%)
NIO   15.88 (-5.08%)
BABA   84.02 (-0.11%)
AMD   67.47 (-0.63%)
T   15.92 (-1.06%)
MU   54.44 (+0.89%)
CGC   3.02 (-3.82%)
F   12.43 (+0.57%)
GE   67.65 (+0.16%)
DIS   99.82 (-1.60%)
AMC   7.25 (-7.41%)
PYPL   93.49 (+0.75%)
PFE   44.05 (-0.92%)
NFLX   233.92 (-2.83%)
S&P 500   3,780.87 (-0.27%)
DOW   30,277.44 (-0.13%)
QQQ   280.67 (-0.52%)
AAPL   145.63 (-0.32%)
MSFT   248.12 (-0.31%)
META   138.05 (-1.59%)
GOOGL   100.75 (-0.88%)
AMZN   120.30 (-0.65%)
TSLA   238.25 (-4.49%)
NVDA   130.79 (-0.67%)
NIO   15.88 (-5.08%)
BABA   84.02 (-0.11%)
AMD   67.47 (-0.63%)
T   15.92 (-1.06%)
MU   54.44 (+0.89%)
CGC   3.02 (-3.82%)
F   12.43 (+0.57%)
GE   67.65 (+0.16%)
DIS   99.82 (-1.60%)
AMC   7.25 (-7.41%)
PYPL   93.49 (+0.75%)
PFE   44.05 (-0.92%)
NFLX   233.92 (-2.83%)
S&P 500   3,780.87 (-0.27%)
DOW   30,277.44 (-0.13%)
QQQ   280.67 (-0.52%)
AAPL   145.63 (-0.32%)
MSFT   248.12 (-0.31%)
META   138.05 (-1.59%)
GOOGL   100.75 (-0.88%)
AMZN   120.30 (-0.65%)
TSLA   238.25 (-4.49%)
NVDA   130.79 (-0.67%)
NIO   15.88 (-5.08%)
BABA   84.02 (-0.11%)
AMD   67.47 (-0.63%)
T   15.92 (-1.06%)
MU   54.44 (+0.89%)
CGC   3.02 (-3.82%)
F   12.43 (+0.57%)
GE   67.65 (+0.16%)
DIS   99.82 (-1.60%)
AMC   7.25 (-7.41%)
PYPL   93.49 (+0.75%)
PFE   44.05 (-0.92%)
NFLX   233.92 (-2.83%)
NASDAQ:AZRX

AzurRx BioPharma - AZRX Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$1.60
$1.74
50-Day Range
$2.40
$41.00
52-Week Range
$3.36
$26.30
Volume
239,703 shs
Average Volume
628,703 shs
Market Capitalization
$15.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
AZRX stock logo

About AzurRx BioPharma (NASDAQ:AZRX) Stock

AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product programs include MS1819, FW-1022: COVID-19 GI infections, and FW-420: Immune Checkpoint Inhibitor Colitis. The company was founded on January 30, 2014 and is headquartered in Delray Beach, FL.

Receive AZRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AzurRx BioPharma and its competitors with MarketBeat's FREE daily newsletter.

AZRX Stock News Headlines

FWBI First Wave BioPharma, Inc.
First Wave BioPharma Inc (FWBI)
First Wave BioPharma Inc
AzurRx BioPharma Changes Name to First Wave BioPharma
AzurRx (AZRX) Announces First Wave Bio Acquisition for $229M
AzurRx BioPharma To Acquire First Wave Bio For $229M
AzurRx BioPharma Announces Reverse Stock Split
AZURRX BIOPHARMA INC COM USD0.0001(AZRX)
See More Headlines

Receive AZRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AzurRx BioPharma and its competitors with MarketBeat's FREE daily newsletter.

AZRX Company Calendar

Today
10/05/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AZRX
Fax
N/A
Employees
12
Year Founded
N/A

Profitability

Net Income
$-32,670,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.76) per share

Miscellaneous

Free Float
8,645,000
Market Cap
$15.39 million
Optionable
Not Optionable
Beta
1.51

Key Executives

  • James E. Sapirstein
    Chairman, President & Chief Executive Officer
  • Daniel H. Schneiderman
    Chief Financial Officer
  • James E. Pennington
    Chief Medical Officer
  • Tony Baca
    Vice President-Clinical Operations
  • Martin Krusin
    Senior Vice President-Corporate Development













AZRX Stock - Frequently Asked Questions

When did AzurRx BioPharma's stock split?

AzurRx BioPharma shares reverse split before market open on Monday, September 13th 2021. The 1-10 reverse split was announced on Monday, September 13th 2021. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 13th 2021. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of AzurRx BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AzurRx BioPharma investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), SCYNEXIS (SCYX), Gran Tierra Energy (GTE), Cogent Biosciences (UMRX), KushCo (KSHB), OrganiGram (OGI), Pennsylvania Real Estate Investment Trust (PEI) and Novan (NOVN).

When did AzurRx BioPharma IPO?

(AZRX) raised $15 million in an initial public offering (IPO) on Friday, September 9th 2016. The company issued 2,100,000 shares at $6.00-$8.00 per share. WallachBeth Capital and Network 1 Financial Securities served as the underwriters for the IPO.

What is AzurRx BioPharma's stock symbol?

AzurRx BioPharma trades on the NASDAQ under the ticker symbol "AZRX."

What is AzurRx BioPharma's stock price today?

One share of AZRX stock can currently be purchased for approximately $1.65.

How much money does AzurRx BioPharma make?

AzurRx BioPharma (NASDAQ:AZRX) has a market capitalization of $15.39 million. The company earns $-32,670,000.00 in net income (profit) each year or ($11.50) on an earnings per share basis.

How can I contact AzurRx BioPharma?

AzurRx BioPharma's mailing address is 760 PARKSIDE AVENUE SUITE 304, BROOKLYN NY, 11226. The official website for the company is www.azurrx.com. The company can be reached via phone at (649) 699-7855 or via email at hans@lifesciadvisors.com.

This page (NASDAQ:AZRX) was last updated on 10/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.